February 2011 Br J Cardiol 2011;18:9-10
BJ Cardio Staff
The study (Lancet 2010;376:1916–22) assessed whether long-term (three year) statin treatment (mainly atorvastatin) is safe and effective in patients thought to have NAFLD. Overall, liver-related adverse effects such as increased levels of liver enzymes or serum transaminases like alanine aminotransferase (ALT) occurred no more often in the group who were given statins. Over three years follow-up, ALT improved or normalised in patients who were given statins, but in the group not taking statins liver tests worsened.
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits